{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:45:01Z","timestamp":1792028701021,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Conventional systemic therapies are valuable options in prostate cancer (PCa); however, such treatments can determine adverse events and toxicity. The observed improvement in overall survival, coupled with PSA reduction and a favorable safety profile in the post-taxane castration-resistant PCa (CRPC) setting has prompted the consideration of PSMA-based radioligand therapy (RLT) earlier in the treatment sequence. In this review, we will describe the literature and ongoing clinical trials regarding the use of PSMA-based RLT in hormone-sensitive PCa (HSPC) including the neoadjuvant, de-novo\/synchronous metastatic, adjuvant, and early BCR settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic literature search on the PubMed\/MEDLINE\/EMBASE and clinicaltrials.gov databases for studies and protocols assessing the role of PSMA-based RLT in HSPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The literature search yielded 140 results. After screening titles and abstracts and applying inclusion and exclusion criteria, we selected 25 papers showing the potentialities of earlier RLT in HSPC, with several ongoing trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early use of PSMA-based RLT holds significant potential in HSPC patients from the neoadjuvant to the BCR setting. In these stages, the lower tumor burden, more frequent exclusive nodal involvement, and higher organ reserve may improve treatment efficacy and allow for treatment combinations while maintaining a less toxic profile.\u00a0<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07083-8","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T22:43:56Z","timestamp":1739313836000},"page":"2723-2735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-0301","authenticated-orcid":false,"given":"Riccardo","family":"Laudicella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1937-9116","authenticated-orcid":false,"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-8692","authenticated-orcid":false,"given":"Irene A","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cacciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-4301","authenticated-orcid":false,"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ficarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9416-6965","authenticated-orcid":false,"given":"Virginia","family":"Liberini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pergolizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Minutoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"7083_CR1","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","volume":"48","author":"JH R\u00fcschoff","year":"2021","unstructured":"R\u00fcschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, et al. What\u2019s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48:4042\u201353. https:\/\/doi.org\/10.1007\/s00259-021-05501-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR2","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1007\/s00259-022-05787-9","volume":"49","author":"R Laudicella","year":"2022","unstructured":"Laudicella R, R\u00fcschoff JH, Ferraro DA, Brada MD, Hausmann D, Mebert I, et al. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI. Eur J Nucl Med Mol Imaging. 2022;49:3917\u201328. https:\/\/doi.org\/10.1007\/s00259-022-05787-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR3","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/tomography8050205","volume":"8","author":"R Laudicella","year":"2022","unstructured":"Laudicella R, La Torre F, Dav\u00ec V, Croc\u00e8 L, Aric\u00f2 D, Leonardi G, et al. Prostate Cancer biochemical recurrence resulted negative on [68Ga]Ga-PSMA-11 but positive on [18F]Fluoromethylcholine PET\/CT. Tomography. 2022;8:2471\u20134. https:\/\/doi.org\/10.3390\/tomography8050205.","journal-title":"Tomography"},{"key":"7083_CR4","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR5","doi-asserted-by":"publisher","first-page":"102698","DOI":"10.1016\/j.ctrv.2024.102698","volume":"124","author":"M Bauckneht","year":"2024","unstructured":"Bauckneht M, Ciccarese C, Laudicella R, Mosillo C, D\u2019Amico F, Anghelone A, et al. Theranostics revolution in prostate cancer: basics, clinical applications, open issues and future perspectives. Cancer Treat Rev. 2024;124:102698. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102698.","journal-title":"Cancer Treat Rev"},{"key":"7083_CR6","doi-asserted-by":"publisher","first-page":"102750","DOI":"10.1016\/j.eucr.2024.102750","volume":"54","author":"R Laudicella","year":"2024","unstructured":"Laudicella R, Minutoli F, Russo S, Siracusa M, Bambaci M, Pagano B, et al. mCRPC progression of disease after [177Lu]Lu-PSMA-617 detected on [18F]Choline: a case of PCa heterogeneity. Urol Case Rep. 2024;54:102750. https:\/\/doi.org\/10.1016\/j.eucr.2024.102750.","journal-title":"Urol Case Rep"},{"key":"7083_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"7083_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"key":"7083_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7083_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"7083_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"7083_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer. Part II-2024 update: treatment of relapsing and metastatic prostate Cancer. Eur Urol. 2024;86:164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","journal-title":"Eur Urol"},{"key":"7083_CR13","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","volume":"20","author":"N Agarwal","year":"2019","unstructured":"Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019;20:1518\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(19)30620-5.","journal-title":"Lancet Oncol"},{"key":"7083_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with Enzalutamide in biochemically recurrent prostate Cancer. N Engl J Med. 2023;389:1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"key":"7083_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2967\/jnumed.124.267526","volume":"65","author":"M Bauckneht","year":"2024","unstructured":"Bauckneht M, Fornarini G, Di Raimondo T, Pardini M, Donegani MI, Banna GL, et al. Brain metabolic correlates of the Off-Target effects of Enzalutamide on the Central Nervous System of patients with advanced prostate Cancer. J Nucl Med. 2024;65:1327. https:\/\/doi.org\/10.2967\/jnumed.124.267526.","journal-title":"J Nucl Med"},{"key":"7083_CR16","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in metastatic prostate Cancer. N Engl J Med. 2019;381:2506\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1911206.","journal-title":"N Engl J Med"},{"key":"7083_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, hormone-sensitive prostate Cancer. N Engl J Med. 2022;386:1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"key":"7083_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:9\u201315. https:\/\/doi.org\/10.1007\/s00259-019-04529-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR19","doi-asserted-by":"publisher","first-page":"e22495","DOI":"10.1096\/fj.202200190R","volume":"36","author":"H Luo","year":"2022","unstructured":"Luo H, Liu Y, Li Y, Zhang C, Yu B, Shao C. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells. FASEB J. 2022;36:e22495. https:\/\/doi.org\/10.1096\/fj.202200190R.","journal-title":"FASEB J"},{"key":"7083_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4:699\u2013715. https:\/\/doi.org\/10.1038\/s43018-023-00539-6.","journal-title":"Nat Cancer"},{"key":"7083_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.123.266391","volume":"65","author":"A Farolfi","year":"2024","unstructured":"Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, et al. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy practice patterns: International Survey of 95 Theranostic centers. J Nucl Med. 2024;65:438\u201345. https:\/\/doi.org\/10.2967\/jnumed.123.266391.","journal-title":"J Nucl Med"},{"key":"7083_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ - Page","year":"2021","unstructured":"- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"7083_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","volume":"6","author":"S Golan","year":"2023","unstructured":"Golan S, Frumer M, Zohar Y, Rosenbaum E, Yakimov M, Kedar D, et al. Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in patients with high-risk prostate Cancer before radical prostatectomy: a single-arm phase 1 trial. Eur Urol Oncol. 2023;6:151\u20139. https:\/\/doi.org\/10.1016\/j.euo.2022.09.002.","journal-title":"Eur Urol Oncol"},{"key":"7083_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Buteau JP, Jackson P, Mitchell C, Oon SF, Alghazo O, et al. Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate Cancer (LuTectomy): a Single-centre, Single-arm, phase 1\/2 study. Eur Urol. 2024;85:217\u201326. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.026.","journal-title":"Eur Urol"},{"key":"7083_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.eururo.2021.06.012","volume":"80","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Das N, Sood A, Singh SK, Goyal S, Madan R, et al. Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume metastatic hormone-sensitive prostate Cancer: time to take the Leap? Eur Urol. 2021;80:390\u20132. https:\/\/doi.org\/10.1016\/j.eururo.2021.06.012.","journal-title":"Eur Urol"},{"key":"7083_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/RLU.0000000000005000","volume":"49","author":"S Satapathy","year":"2024","unstructured":"Satapathy S, Yadav MP, Ballal S, Sahoo RK, Bal C. Promising therapeutic activity of 177 Lu-PSMA-617 in Synchronous High-volume metastatic hormone-sensitive prostate Cancer: a pilot experience. Clin Nucl Med. 2024;49:131\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000005000.","journal-title":"Clin Nucl Med"},{"key":"7083_CR27","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet. 2024;25:1267\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(24)00440-6.","journal-title":"Lancet"},{"issue":"7","key":"7083_CR28","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s00259-023-06165-9","volume":"50","author":"M Sathekge","year":"2023","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Mokoala K, Reed J, et al. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023;50(7):2210\u20138. https:\/\/doi.org\/10.1007\/s00259-023-06165-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","volume":"23","author":"ECA van der Sar","year":"2023","unstructured":"van der Sar ECA, Braat AJAT, van der Voort-van Zyp JRN, van der Veen BS, van Leeuwen PJ, de Vries-Huizing DMV, et al. Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial). BMC Cancer. 2023;23:268. https:\/\/doi.org\/10.1186\/s12885-023-10725-5.","journal-title":"BMC Cancer"},{"key":"7083_CR30","doi-asserted-by":"publisher","first-page":"102752","DOI":"10.1016\/j.eucr.2024.102752","volume":"54","author":"A Tulipan","year":"2024","unstructured":"Tulipan A, Kratochwil C, Lilleby J, Lilleby W. A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer. Urol Case Rep. 2024;54:102752. https:\/\/doi.org\/10.1016\/j.eucr.2024.102752.","journal-title":"Urol Case Rep"},{"key":"7083_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.clgc.2017.09.005","volume":"16","author":"MO Demirkol","year":"2018","unstructured":"Demirkol MO, Kiremit MC, Acar O, Falay O, Ucar B, Esen T. Local salvage treatment of Post-brachytherapy recurrent prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177. Clin Genitourin Cancer. 2018;16:99\u2013102. https:\/\/doi.org\/10.1016\/j.clgc.2017.09.005.","journal-title":"Clin Genitourin Cancer"},{"key":"7083_CR32","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","volume":"27","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9 BM, Peters SMB, Muselaers CHJ, van Oort IM, Janssen MJR, Sedelaar JPM, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate Cancer: a prospective pilot study. Clin Cancer Res. 2021;27:3595\u2013601. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4298.","journal-title":"Clin Cancer Res"},{"key":"7083_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, Priv\u00e9 BM, de Bakker M, de Lange F, Jentzen W, Eek A, et al. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49:460\u20139. https:\/\/doi.org\/10.1007\/s00259-021-05471-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s12149-021-01593-9","volume":"35","author":"M Tuncel","year":"2021","unstructured":"Tuncel M, Telli T, Tuncal\u0131 M\u00c7, Karabulut E. Predictive factors of tumor sink effect: insights from 177Lu-Prostate-specific membrane antigen therapy. Ann Nucl Med. 2021;35:529\u201339. https:\/\/doi.org\/10.1007\/s12149-021-01593-9.","journal-title":"Ann Nucl Med"},{"key":"7083_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/cancers15010297","volume":"15","author":"A Banda","year":"2022","unstructured":"Banda A, Priv\u00e9 BM, Allach Y, Uijen MJM, Peters SMB, Loeff CC, et al. PSMA-RLT in patients with metastatic hormone-sensitive prostate Cancer: a retrospective study. Cancers (Basel). 2022;15:297. https:\/\/doi.org\/10.3390\/cancers15010297.","journal-title":"Cancers (Basel)"},{"key":"7083_CR36","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","volume":"64","author":"M Grkovski","year":"2023","unstructured":"Grkovski M, O\u2019Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, et al. Lesion dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate Cancer. J Nucl Med. 2023;64:1779\u201387. https:\/\/doi.org\/10.2967\/jnumed.123.265763.","journal-title":"J Nucl Med"},{"key":"7083_CR37","doi-asserted-by":"publisher","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","volume":"41","author":"ST Tagawa","year":"2023","unstructured":"Tagawa ST, Sartor AO, Saad F, Reid AH, Sakharova OV, Feng FY, et al. PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. JCO. 2023;41:TPS5116\u20135116. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS5116.","journal-title":"JCO"},{"key":"7083_CR38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1186\/s13063-021-05733-4","volume":"22","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9 BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, van Gemert WA, et al. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials. 2021;22:768. https:\/\/doi.org\/10.1186\/s13063-021-05733-4.","journal-title":"Trials"},{"key":"7083_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bju.15988","volume":"132","author":"TM Ma","year":"2023","unstructured":"Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, et al. LUNAR: a randomized phase 2 study of 177 Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate Cancer (clinical trial protocol). BJU Int. 2023;132:65\u201374. https:\/\/doi.org\/10.1111\/bju.15988.","journal-title":"BJU Int"},{"key":"7083_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12885-023-10851-0","volume":"23","author":"LC Mendez","year":"2023","unstructured":"Mendez LC, Dhar A, Laidley D, Moussa M, Gomez JA, Chin J, et al. The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I\/II study (ROADSTER). BMC Cancer. 2023;23:362. https:\/\/doi.org\/10.1186\/s12885-023-10851-0.","journal-title":"BMC Cancer"},{"key":"7083_CR41","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","volume":"20","author":"L Baratto","year":"2018","unstructured":"Baratto L, Jadvar H, Iagaru A. Prostate Cancer Theranostics Targeting gastrin-releasing peptide receptors. Mol Imaging Biol. 2018;20:501\u20139. https:\/\/doi.org\/10.1007\/s11307-017-1151-1.","journal-title":"Mol Imaging Biol"},{"key":"7083_CR42","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/diagnostics13061175","volume":"13","author":"R Laudicella","year":"2023","unstructured":"Laudicella R, Spataro A, Croc\u00e8 L, Giacoppo G, Romano D, Dav\u00ec V, et al. Preliminary findings of the role of FAPi in prostate Cancer theranostics. Diagnostics (Basel). 2023;13:1175. https:\/\/doi.org\/10.3390\/diagnostics13061175.","journal-title":"Diagnostics (Basel)"},{"key":"7083_CR43","doi-asserted-by":"publisher","first-page":"TPS5087","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5087","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Metser U, Czernin J, Calais J, Prasad V, Eiber M, et al. Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH). JCO. 2021;39:TPS5087\u20135087. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS5087.","journal-title":"JCO"},{"key":"7083_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:563\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"key":"7083_CR45","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane Antigen Heterogeneity and DNA repair defects in prostate Cancer. Eur Urol. 2019;76:469\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030.","journal-title":"Eur Urol"},{"key":"7083_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06856-x","author":"NJ Rupp","year":"2024","unstructured":"Rupp NJ, Freiberger SN, Ferraro DA, Laudicella R, Heimer J, Muehlematter UJ, et al. Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06856-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","volume":"215","author":"C Kaittanis","year":"2018","unstructured":"Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215:159\u201375. https:\/\/doi.org\/10.1084\/jem.20171052.","journal-title":"J Exp Med"},{"key":"7083_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","volume":"8","author":"K L\u00fcckerath","year":"2018","unstructured":"L\u00fcckerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8:96. https:\/\/doi.org\/10.1186\/s13550-018-0451-z.","journal-title":"EJNMMI Res"},{"key":"7083_CR49","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/pros.23522","volume":"78","author":"B Kranzb\u00fchler","year":"2018","unstructured":"Kranzb\u00fchler B, Salemi S, Umbricht CA, M\u00fcller C, Burger IA, Sulser T, Eberli D. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate. 2018;78:758\u201365. https:\/\/doi.org\/10.1002\/pros.23522.","journal-title":"Prostate"},{"key":"7083_CR50","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7083_CR51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2967\/jnumed.123.267321","volume":"65","author":"R Seifert","year":"2024","unstructured":"Seifert R, Telli T, Lapa C, Desaulniers M, Hekimsoy T, Weber WA, et al. Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: a German Multicenter Study. J Nucl Med. 2024;65:909\u201316. https:\/\/doi.org\/10.2967\/jnumed.123.267321.","journal-title":"J Nucl Med"},{"key":"7083_CR52","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted \u03b1-Therapy of metastatic castration-resistant prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58:1624\u201331. https:\/\/doi.org\/10.2967\/jnumed.117.191395.","journal-title":"J Nucl Med"},{"key":"7083_CR53","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2967\/jnumed.123.267206","volume":"65","author":"H Rathke","year":"2024","unstructured":"Rathke H, Winter E, Bruchertseifer F, R\u00f6hrich M, Giesel FL, Haberkorn U, et al. Deescalated 225Ac-PSMA-617 Versus 177Lu\/225Ac-PSMA-617 cocktail therapy: a single-center retrospective analysis of 233 patients. J Nucl Med. 2024;65:1057\u201363. https:\/\/doi.org\/10.2967\/jnumed.123.267206.","journal-title":"J Nucl Med"},{"key":"7083_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(23)00638-1.","journal-title":"Lancet Oncol"},{"key":"7083_CR55","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2967\/jnumed.123.267189","volume":"65","author":"MR Griffiths","year":"2024","unstructured":"Griffiths MR, Pattison DA, Latter M, Kuan K, Taylor S, Tieu W, et al. First-in-human 212Pb-PSMA-Targeted \u03b1-Therapy SPECT\/CT Imaging in a patient with metastatic castration-resistant prostate Cancer. J Nucl Med. 2024;65:664. https:\/\/doi.org\/10.2967\/jnumed.123.267189.","journal-title":"J Nucl Med"},{"key":"7083_CR56","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s13139-023-00804-7","volume":"57","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Scott AM. 161Tbunleashedeashed: a Promising New Player itheranosticsostiprostateocancerCancer. Nucl Med Mol Imaging. 2023;57:168\u201371. https:\/\/doi.org\/10.1007\/s13139-023-00804-7.","journal-title":"Nucl Med Mol Imaging"},{"key":"7083_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00913-8","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Williams SG, Macdonald S, Keam SP, Lawrentschuk N, Au L, et al. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. Nat Rev Urol. 2024. https:\/\/doi.org\/10.1038\/s41585-024-00913-8.","journal-title":"Nat Rev Urol"},{"key":"7083_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.critrevonc.2019.03.008","volume":"139","author":"A Fiorentino","year":"2019","unstructured":"Fiorentino A, Laudicella R, Ciurlia E, Annunziata S, Lancellotta V, Mapelli P, et al. Positron emission tomography with computed tomography imaging (PET\/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Crit Rev Oncol Hematol. 2019;139:117\u201324. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.008.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7083_CR59","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","volume":"65","author":"F Pouliot","year":"2024","unstructured":"Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, et al. Intrapatient Intermetastatic Heterogeneity determined by Triple-Tracer PET imaging in mCRPC patients and correlation to Survival: the 3TMPO cohort study. J Nucl Med. 2024;65:1710\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.268020.","journal-title":"J Nucl Med"},{"key":"7083_CR60","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023;24:1266\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(23)00451-5.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07083-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07083-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07083-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T06:17:40Z","timestamp":1748413060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07083-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7083"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07083-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for the publication of images was received from the participant who appeared in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This is a literature review and therefore no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}